# Micro–nano integrated platforms for osteoarthritis therapy: From spatial manipulation to cellular reprogramming

**Authors:** Zhijian Shi, Jiayou Chen, Haochi Lun, Rongji Liang, Jingtao Huang, Quan Lin, Wei Li, Zhenhan Deng, Jianjing Lin

PMC · DOI: 10.1016/j.mtbio.2026.102963 · 2026-02-23

## TL;DR

This paper reviews micro-nano composite systems for osteoarthritis therapy, focusing on how they overcome biological barriers and enable precise cellular control.

## Contribution

The paper introduces a new scientific paradigm for precision regenerative medicine using micro-nano integrated platforms.

## Key findings

- Micro-nano platforms enable prolonged joint retention and deep cartilage matrix infiltration.
- These systems modulate macrophages and stem cells for immunomodulation and tissue repair.
- Biomimetic properties of micro-nano architectures support endogenous cartilage regeneration.

## Abstract

Clinical intervention for osteoarthritis (OA) has long been hampered by complex intra-articular physiological barriers, including rapid synovial clearance, the dense penetration resistance of the cartilage extracellular matrix (ECM), and a progressively deteriorating pro-inflammatory microenvironment. Conventional single-scale delivery systems frequently struggle to balance sustained retention with deep tissue penetration. Recently, micro-nano composite structures—engineered through the sophisticated integration of microscale matrices and nanoscale functional units—have catalyzed a paradigm shift from passive “space-filling” to active “fate modulation.” This review systematically delineates the recent advancements in micro-nano platforms for OA therapy. We first evaluate how advanced fabrication strategies, such as microfluidics, 3D bioprinting, and hierarchical emulsification, govern the spatiotemporal arrangement of these structures. Subsequently, we explore the mechanisms by which these trans-scale systems achieve prolonged joint residence, deep ECM infiltration, and precise immunomodulation of macrophages and stem cells. Furthermore, the roles of micro-nano architectures in recapitulating the biomimetic properties (topological, mechanical, and biochemical) of native cartilage and stimulating endogenous repair are highlighted. Finally, we provide a critical appraisal of the challenges hindering clinical translation, including scalability, biosafety margins, and the future of intelligent closed-loop designs. The development of micro-nano composite systems not only offers high-efficiency “cell-free therapy” for OA but also establishes a novel scientific paradigm for precision regenerative medicine in degenerative diseases.

Image 1

## Linked entities

- **Diseases:** osteoarthritis (MONDO:0005178)

## Full-text entities

- **Genes:** BMAL1 (basic helix-loop-helix ARNT like 1) [NCBI Gene 406] {aka ARNTL, ARNTL1, BMAL1c, JAP3, MOP3, PASD3}, KEAP1 (kelch like ECH associated protein 1) [NCBI Gene 9817] {aka INrf2, KLHL19}, SOX9 (SRY-box transcription factor 9) [NCBI Gene 6662] {aka CMD1, CMPD1, ENH13, SRA1, SRXX2, SRXY10}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, CD86 (CD86 molecule) [NCBI Gene 942] {aka B7-2, B7.2, B70, BU63, CD28LG2, CD86 v6}, TGFB3 (transforming growth factor beta 3) [NCBI Gene 7043] {aka ARVD, ARVD1, LDS5, RNHF, TGF-beta3}, KLRK1 (killer cell lectin like receptor K1) [NCBI Gene 22914] {aka CD314, D12S2489E, KLR, NKG2-D, NKG2D}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, ACAN (aggrecan) [NCBI Gene 176] {aka AGC1, AGCAN, CSPG1, CSPGCP, MSK16, SEDK}, MRC1 (mannose receptor C-type 1) [NCBI Gene 4360] {aka CD206, CLEC13D, CLEC13DL, MMR, MRC1L1, bA541I19.1}, TXNRD2 (thioredoxin reductase 2) [NCBI Gene 10587] {aka GCCD5, SELZ, TR, TR-BETA, TR3, TRXR2}, NFE2L2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 4780] {aka IMDDHH, NRF2, Nrf-2}, ISYNA1 (inositol-3-phosphate synthase 1) [NCBI Gene 51477] {aka INO1, INOS, IPS, IPS 1, IPS-1}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, SIRT3 (sirtuin 3) [NCBI Gene 23410] {aka SIR2L3}, SREBF2 (sterol regulatory element binding transcription factor 2) [NCBI Gene 6721] {aka SREBP-2, SREBP2, bHLHd2}, MIR148A (microRNA 148a) [NCBI Gene 406940] {aka MIRN148, MIRN148A, hsa-mir-148, mir-148a}, ADAMTS5 (ADAM metallopeptidase with thrombospondin type 1 motif 5) [NCBI Gene 11096] {aka ADAM-TS 11, ADAM-TS 5, ADAM-TS5, ADAMTS-11, ADAMTS-5, ADAMTS11}, GPX4 (glutathione peroxidase 4) [NCBI Gene 2879] {aka GPx-4, GSHPx-4, MCSP, PHGPx, SMDS, snGPx}, HSPA5 (heat shock protein family A (Hsp70) member 5) [NCBI Gene 3309] {aka BIP, GRP78, HEL-S-89n}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, PRG4 (proteoglycan 4) [NCBI Gene 10216] {aka CACP, HAPO, JCAP, MSF, SZP}, GPX1 (glutathione peroxidase 1) [NCBI Gene 2876] {aka GPXD, GSHPX1}, CXCL12 (C-X-C motif chemokine ligand 12) [NCBI Gene 6387] {aka IRH, PBSF, SCYB12, SDF1, TLSF, TPAR1}, SOD3 (superoxide dismutase 3) [NCBI Gene 6649] {aka EC-SOD}, CD44 (CD44 molecule (IN blood group)) [NCBI Gene 960] {aka CDW44, CSPG8, ECM-III, ECMR-III, H-CAM, HCELL}, SLC7A11 (solute carrier family 7 member 11) [NCBI Gene 23657] {aka CCBR1, xCT}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, FGB (fibrinogen beta chain) [NCBI Gene 2244] {aka HEL-S-78p}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, PLG (plasminogen) [NCBI Gene 5340] {aka HAE4}, DDIT3 (DNA damage inducible transcript 3) [NCBI Gene 1649] {aka AltDDIT3, C/EBPzeta, CEBPZ, CHOP, CHOP-10, CHOP10}, CLEC7A (C-type lectin domain containing 7A) [NCBI Gene 64581] {aka BGR, CANDF4, CD369, CLECSF12, DECTIN1, SCARE2}, COL2A1 (collagen type II alpha 1 chain) [NCBI Gene 1280] {aka ACG2, ANFH, ANFH1, AOM, COL11A3, EDMMD}, CD163 (CD163 molecule) [NCBI Gene 9332] {aka M130, MM130, SCARI1}, CLOCK (clock circadian regulator) [NCBI Gene 9575] {aka KAT13D, bHLHe8}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, MMP13 (matrix metallopeptidase 13) [NCBI Gene 4322] {aka CLG3, MANDP1, MDST, MMP-13}, ARG1 (arginase 1) [NCBI Gene 383], Zein [NCBI Gene 732802], NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, BMP2 (bone morphogenetic protein 2) [NCBI Gene 650] {aka BDA2, BMP2A, SSFSC, SSFSC1}, FGFR2 (fibroblast growth factor receptor 2) [NCBI Gene 2263] {aka BBDS, BEK, BFR-1, CD332, CEK3, CFD1}, TRPV4 (transient receptor potential cation channel subfamily V member 4) [NCBI Gene 59341] {aka BCYM3, CMT2C, HMSN2C, OTRPC4, SMAL, SPSMA}
- **Diseases:** RA (MESH:D001172), arthritis (MESH:D001168), chronic synovitis (MESH:D013585), cardiovascular, renal, and gastrointestinal toxicities (MESH:D005767), osteoporosis (MESH:D010024), joint damage (MESH:D007592), toxicities (MESH:D064420), embolic (MESH:D004617), chronic (MESH:D002908), YLDs (MESH:D009069), degenerative disease (MESH:D019636), Disease (MESH:D004194), OA inflammation (MESH:D007249), mitochondrial dysfunction (MESH:D028361), pain (MESH:D010146), obesity (MESH:D009765), hypoxic (MESH:D002534), OA (MESH:D010003), metabolic abnormalities (MESH:D008659), arthritic (MESH:D015535), Cartilage (MESH:D002357), hypoxia (MESH:D000860)
- **Chemicals:** Safranin O (MESH:C009195), graphene (MESH:D006108), H2O2 (MESH:D006861), DS (MESH:D003903), superoxide (MESH:D013481), DAF-FM-DA (-), ruthenium (MESH:D012428), RGD (MESH:C047981), glycosaminoglycan (MESH:D006025), hydroxychloroquine (MESH:D006886), silica (MESH:D012822), JC-1 (MESH:C068624), DOTAP (MESH:C070046), MOF (MESH:C037042), SA (MESH:D000077145), amino acids (MESH:D000596), DXM (MESH:D003907), polyester (MESH:D011091), PS (MESH:D010718), Selenium (MESH:D012643), celecoxib (MESH:D000068579), PCL (MESH:C016240), Hydroxyapatite (MESH:D017886), Dextran Sulfate (MESH:D016264), TUDCA (MESH:C031655), ATP (MESH:D000255), OH (MESH:C031356), W (MESH:D014414), lipid (MESH:D008055), PLGA (MESH:D000077182), FA (MESH:D005492), ROS (MESH:D017382), calcium (MESH:D002118), manganese (MESH:D008345), trehalose (MESH:D014199), Magnesium (MESH:D008274), Chondroitin Sulfate (MESH:D002809), GA (MESH:C031149), metal (MESH:D008670), itaconate (MESH:C005229), alginate (MESH:D000464), O (MESH:D010100), KGN (MESH:C572342), phosphate (MESH:D010710), CS (MESH:D048271), prolamine (MESH:D010665), FU (MESH:C007789), Cy5.5 (MESH:C098793), LA (MESH:D019344), polysaccharide (MESH:D011134), PGE (MESH:D011458), RES (MESH:D012211), TCA (MESH:D014233), polymer (MESH:D011108), ester (MESH:D004952), hydrazine (MESH:C029424), linolenic acid (MESH:D017962), MTX (MESH:D008727), hydrazone (MESH:D006835), DIC (MESH:D004008)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** Jurkat T — Homo sapiens (Human), Childhood T acute lymphoblastic leukemia, Cancer cell line (CVCL_0065)

## Figures

10 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12966721/full.md

---
Source: https://tomesphere.com/paper/PMC12966721